Business Context and Reporting Period
This Form 6-K filing by GSK plc (a Foreign Private Issuer) reports a transaction in the company's own shares. The filing date is March 5, 2025, covering share purchases executed on March 4, 2025. The company is headquartered in London, United Kingdom.
Key Financial Metrics and Transaction Details
The filing details a specific share buyback transaction rather than providing comprehensive financial statements (revenue, profit, or cash flow are not included in this document).
- Shares Purchased: 547,800 ordinary shares of 31½ pence each.
- Price Range: Lowest price paid was 1,479.50 GBp; highest price paid was 1,523.50 GBp.
- Average Price: Volume-weighted average price paid was 1,508.65 GBp.
- Trading Venue: London Stock Exchange (XLON).
- Broker: Citigroup Global Markets Limited.
- Treasury Shares Held: Following this purchase, GSK holds 174,109,205 ordinary shares in treasury.
- Shares in Issue: 4,141,068,225 ordinary shares (excluding treasury shares).
- Total Voting Rights: 4,141,068,225.
Material Changes and Program Progress
This purchase was executed pursuant to a non-discretionary agreement entered into with the broker on February 24, 2025. Since the inception of this specific agreement on February 24, 2025, the company has purchased an aggregate of 5,038,902 ordinary shares. The filing does not provide comparative financial data against prior periods as it is a transaction report.
Guidance, Outlook, and Risks
The filing contains no new financial guidance, outlook, or management commentary regarding operational performance. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially from projections due to risks described in the company's 2023 Annual Report on Form 20-F and Q4 2024 results.
Investor Verification Checklist
- Verify the total number of treasury shares held (174,109,205) against the company's latest capital structure disclosures.
- Confirm the remaining authorization under the current buyback program, noting 5,038,902 shares have been purchased since February 24, 2025.
- Review the "Risk factors" section in the 2023 Form 20-F and Q4 2024 results for context on the forward-looking statement disclaimer.
- Check the denominator for shareholder notification thresholds under FCA Disclosure Guidance and Transparency Rules, which is currently 4,141,068,225 voting rights.